Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Perrotte

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Oncology (Toronto, Ont.)|May 30, 2009
Sorafenib in the management of metastatic renal cell carcinomaC Guevremont, C Jeldres, P Perrotte, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 13, 2011
[Treatment of metastatic renal cell carcinoma]R Thuret, C Maurin, M Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 1999
Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and scheduleJ W Slaton, P Perrotte, K Inoue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapyL L Pisters, P Perrotte, S M Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factorK Inoue, P Perrotte, C G Wood, et al.
Cancer Gene Therapy|July 27, 1999
Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouseM Wood, P Perrotte, E Onishi, et al.
The Journal of Urology|July 20, 1999
Quality of life after salvage cryotherapy: the impact of treatment parametersP Perrotte, M S Litwin, E J McGuire, et al.
Urology|June 28, 2000
Biosafety of in vivo adenovirus-p53 intravesical administration in miceP Perrotte, M Wood, J W Slaton, et al.
The Canadian Journal of Urology|November 9, 2005
French-Canadian linguistic validation of the NIH Chronic Prostatitis Symptom IndexP I Karakiewicz, P Perrotte, L Valiquette, et al.
Cancer Research|March 4, 1998
Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administrationC P Dinney, D R Bielenberg, P Perrotte, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Oncology (Toronto, Ont.)|May 30, 2009
Sorafenib in the management of metastatic renal cell carcinomaC Guevremont, C Jeldres, P Perrotte, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 13, 2011
[Treatment of metastatic renal cell carcinoma]R Thuret, C Maurin, M Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 1999
Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and scheduleJ W Slaton, P Perrotte, K Inoue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapyL L Pisters, P Perrotte, S M Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factorK Inoue, P Perrotte, C G Wood, et al.
Cancer Gene Therapy|July 27, 1999
Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouseM Wood, P Perrotte, E Onishi, et al.
The Journal of Urology|July 20, 1999
Quality of life after salvage cryotherapy: the impact of treatment parametersP Perrotte, M S Litwin, E J McGuire, et al.
Urology|June 28, 2000
Biosafety of in vivo adenovirus-p53 intravesical administration in miceP Perrotte, M Wood, J W Slaton, et al.
The Canadian Journal of Urology|November 9, 2005
French-Canadian linguistic validation of the NIH Chronic Prostatitis Symptom IndexP I Karakiewicz, P Perrotte, L Valiquette, et al.
Cancer Research|March 4, 1998
Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administrationC P Dinney, D R Bielenberg, P Perrotte, et al.
Pageof 3